Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
Published: June 2014 Pages: 107 Contact Us: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 Mail us: sales@reportsandintelligence.com Detailed report at: http://www.reportsandintelligence.com/companion-diagnostictechnologies-market
Companion diagnostics are a form of in-vitro diagnostics which provide data about the therapeutic reactions of patients for a particular treatment. Companion diagnostics market is still developing, and it is expected to reach a market value of $3.5 billion by 2020 from a market value of $1.1 billion in the year 2013, registering a CAGR of 20% during 2014-2020. The global companion diagnostic market is divided on the basis of technology, geography and indication (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is growing rapidly. Factors that are contributing towards the growth of market are invention of biomarkers and co-development of drug and corresponding diagnostic. However, high cost of drug development would deter the market growth. Opportunities for the market would be in the development of companion diagnostics for hereditary conditions numerous central nervous system conditions. Companion Diagnostics Indication Market Analysis Companion diagnostics is divided based on its utilization for indication, for example, oncology, cardiovascular conditions, focal sensory system evidences, irritation and virology. Oncology is the maximum revenue generating segment, as most of the CD technology has been developed to invent oncology biomarkers. Increasing research and development of targeted drugs is the main driving factor for this market. Companion Diagnostics Technology Market Analysis The report segments the companion diagnostics technology market on the basis of Immunohistochemistry and Molecular diagnostics. Atomic diagnostics would be the quickest developing and the maximum income generator, basically because of the utilization of procedures, for example, constant PCR, In Situ Hybridization and cutting edge sequencing. Different components helping the development are mechanical progressions in atomic diagnostics, which has brought about expanded precision and exactness and likewise decreased expense of testing through these methods. Companion Diagnostics Geography Market Analysis Companion Diagnostics market has been sectioned geographically into North America, Europe, Asia Pacific and LAMEA. North America has the significant piece of the pie of 43.97%, followed by Europe, which represented something like 38% of the general CD market in 2013. North America and Europe together represented in excess of 82% in the worldwide CD market in 2013 and they would keep on being the significant markets until 2020.. Competitive Analysis A detailed research of key players has demonstrated that most of the companies in this business sector are concentrating on coordinated efforts with drug organizations. The top
players included in the report are Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, biomerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies. High Level Analysis The report is concentrating on the patterns in diagnosis and technology of various indications, which are driving the development of the companion diagnostics market. Research of the business is focused around others five force model that shows the negotiating power of the suppliers is high, as the items delivered are very distinguished. The risk of new entrants is low as noteworthy innovative work is needed for creating diagnostic tests. Further, the cash flow required is also high. These components make it difficult for new organizations to enter the business. The risk of substitutes is low in this business sector as companion diagnostics are created for particular biomarkers and the products are highly distinguished. Since it is an emerging market with few companies, the completion is not high. Government regulations are favoring utilization of companion diagnostics for the deciding a specific treatment. Organizations are concentrating on joint efforts with pharmaceutical organizations as a key procedure to further bolster the market growth. Reason for doing the study Companion diagnostics are a critical part of the personalized treatment approach and are fundamental to identify therapeutic response to a specific medication. Rising cases of diseases and healthcare awareness would increase the market scope.
KEY BENEFITS • In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market • Analysis of the market by geography would help in making region specific plans • Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market • Porter’s five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions • Top factors impacting the market would help in making decisions for business development KEY DELIVERABLES MARKET BY INDICATIONS • Oncology
Cardiovascular • Central Nervous System • Auto immune & Inflammation • Virology • Others MARKET BY TECHNOLOGY • Immunohistochemistry • Molecular diagnostics o In situ Hybridization FISH CISH o Real time PCR o Gene Sequencing MARKET BY GEOGRAPHY • North America • Europe • Asia Pacific • LAMEA •
Table of Content CHAPTER 1. INTRODUCTION 1.1 Report description 1.2 Key market segments 1.3 Research methodology 1.3.1 Secondary research 1.3.2 Primary research 1.3.3 Analyst tools and models
CHAPTER 2. EXECUTIVE SUMMARY CHAPTER 3. MARKET OVERVIEW
3.1 Market Definition and Scope 3.2 Companion Diagnostics for Metabolic Diseases 3.3 Novel trends and technologies in companion diagnostics assay development 3.4 Companion diagnostics as a new trend in personalized medicine 3.5 Biomarkers market as basis for the companion diagnostics industry 3.6 Key Findings 3.6.1 Top Factors Impacting The Companion Diagnostic Market
3.6.2 Top Winning Strategies 3.7 Porter’s five forces analysis 3.7.1 High switching cost leads to higher bargaining power of suppliers 3.7.2 Highly differentiated products leads to lower bargaining power of buyers 3.7.3 Specificity of diagnostics lowers the threat of substitutes 3.7.4 Higher capital investment leads to lesser threat of entrants 3.7.5 Few competitors leads to low competition among players 3.8 Government Regulations 3.8.1 FDA regulations 3.8.2 Europe 3.8.3 Japan 3.8.4 China 3.9 Value Chain Analysis 3.10 Case Study 3.11 Drivers 3.11.1 Increased popularity of Personalized medicine 3.11.2 Increasing cases of adverse drug reactions(ADRs) 3.11.3 Increase in the Discovery of Biomarkers as drug targets. 3.11.4 Rising success of co-development drugs speedily approved by the FDA 3.11.5 Technological advancements 3.11.6 Rising incidences of diseases 3.12 Restraints 3.12.1 High Cost in research and development of drugs 3.12.1.1 Economic and scientific obstacles 3.12.2 Opportunities 3.12.2.1 Opportunities in treatment of neurodegenerative diseases 3.12.2.2 Companion diagnostics for hereditary mutations
CHAPTER 4. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS 4.1 Oncology 4.1.1 Companion diagnostics oncology market by geography, 4.1.2 Breast Cancer 4.1.2.1 companion diagnostics breast cancer market by geography 4.1.3 Lung Cancer 4.1.3.1 companion diagnostics lung cancer market by geography 4.1.4 Colorectal Cancer 4.1.4.1 companion diagnostics Colorectal Cancer market by geography 4.1.5 Gastric cancer 4.1.5.1 companion diagnostics Gastric Cancer market by geography 4.1.6 Melanomas 4.1.6.1 companion diagnostics Melanoma market by geography 4.2 Inflammation and Autoimmune diseases 4.2.1 Companion diagnostics inflammation market by geography 4.3 Companion diagnostics in cardiovascular diseases 4.3.1 Companion diagnostics tests for warfarin
4.3.2 Companion diagnostics cardiovascular market by geography 4.4 Companion diagnostics in CNS disorders 4.4.1 Companion diagnostics CNS market by geography 4.5 Companion diagnostics tests in virology diseases 4.5.1 Companion diagnostics virology market by geography 4.6 Others 4.6.1 Companion diagnostics others market by geography
CHAPTER 5. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 5.1 Companion diagnostics technology market by geography 5.2 Immunohistochemistry 5.2.1 Companion diagnostics Immmunohistochemistry market by geography 5.3 Molecular Diagnostics 5.3.1 Companion diagnostics molecular diagnostics market by types 5.3.2 Companion diagnostics Molecular Diagnostics market by geography 5.3.3 In-situ Hybridization 5.3.3.1 Fluorescent In-situ Hybridization(FISH) 5.3.3.2 CISH (Chromogenic In-Situ Hybridization) 5.3.3.3 Companion diagnostics In situ Hybridization market by geography 5.3.4 Real Time PCR 5.3.4.1 Companion diagnostics RT PCR market by geography 5.3.5 Gene Sequencing 5.3.5.1 Companion diagnostics Sequencing market by geography 5.3.6 Others 5.3.6.1 Others molecular companion diagnostics market by geography
CHAPTER 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY 6.1 North America 6.1.1 Companion diagnostics North America market by indication 6.2 Europe 6.2.1 Companion diagnostics Europe market by indication 6.3 Asia Pacific 6.3.1 Companion diagnostics Asia Pacific market by indication 6.4 RoW 6.4.1 Companion diagnostics RoW market by indication
CHAPTER 7. COMPANY PROFILES 7.1 Qiagen 7.1.1 Company Overview: 7.1.2 Company Snapshot 7.1.3 Business Performance 7.1.4 Strategy move and development 7.1.4.1 Principal strategies Collaborations 7.1.4.2 Secondary Strategies Approval
7.1.5 SWOT Analysis of Qiagen 7.2 Dako (Agilent Technologies) 7.2.1 Company Overview 7.2.2 Company Snapshot 7.2.3 Business Performance 7.2.4 Strategic Moves and Development 7.2.4.1 Principal strategies Collaboration 7.2.4.2 Secondary Strategies Approval 7.2.5 SWOT Analysis of Dako 7.3 Roche 7.3.1 Company overview 7.3.2 Company Snapshot 7.3.3 Business Performance 7.3.4 Strategies move and development 7.3.5 SWOT analysis of Roche 7.4 Abbott Laboratories, Inc. 7.4.1 Company Overview 7.4.2 Company Snapshot 7.4.3 Business Performance 7.4.4 Principal Strategies Collaboration 7.4.5 SWOT Analysis of Abbot 7.5 BioMerieux 7.5.1 Company Overview 7.5.2 Company snapshot: 7.5.3 Business Performance 7.5.4 Strategies and development Approval 7.5.5 SWOT Analysis of BioMerieux, 7.6 Ventana Medical Systems 7.6.1 Company Profile 7.6.2 Company Snapshot 7.6.3 Business Performance 7.6.4 Strategies and development 7.6.5 SWOT Analysis of Ventana 7.7 Myriad Genetics, Inc. 7.7.1 Company Overview 7.7.2 Company snapshot 7.7.3 Business Performance 7.7.4 Strategies and development 7.7.5 SWOT Analysis of Myraid 7.8 Resonance Health Ltd 7.8.1 Company Overview 7.8.2 Company Snapshot 7.8.3 Strategies move and development 7.8.4 SWOT Analysis of Ferriscan 7.9 Leica Microsystems
7.9.1 Company overview 7.9.2 Company Snapshot 7.9.3 Strategies move and Development 7.9.4 SWOT Analysis of Leica Microsystems 7.10 Life Technologies 7.10.1 Company Overview 7.10.2 Company Snapshot 7.10.3 Business performance 7.10.4 Strategies move and Development 7.10.5 SWOT Analysis of Life Technologies
LIST OF TABLES
TABLE 1 GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020 ($MILLION) TABLE 2 COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020, ($MILLION) TABLE 4 COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020, ($MILLION) TABLE 5 COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 6 COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 7 COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 8 COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 9 COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 10 COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 11 COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 12 COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 13 COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 14 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 15 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020 ($MILLION) TABLE 16 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 17 COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 20132020 ($MILLION) TABLE 18 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES 2013-2020 ($MILLION) TABLE 19 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 20 COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 21 COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 22 COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 23 OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020
($MILLION) TABLE 24 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION) TABLE 25 COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION) TABLE 26 COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION) TABLE 27 COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION) TABLE 28 COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION) TABLE 29 QIAGEN SNAPSHOT TABLE 30 DAKO COMPANY SNAPSHOT TABLE 31 ROCHE COMPANY SNAPSHOT TABLE 32 ABBOTT COMPANY SNAPSHOT TABLE 33 BIOMERIEUX COMPANY SNAPSHOT TABLE 34 VENTANA COMPANY SNAPSHOT TABLE 35 MYRIAD COMPANY SNAPSHOT TABLE 36 RESONANCE COMPANY SNAPSHOT TABLE 37 LEICA COMPANY SNAPSHOT TABLE 38 LIFE TECHNOLOGIES COMPANY SNAPSHOT
LIST OF FIGURES
FIG.1 COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE FIG.2 EFFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS FIG.3 LIST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES FIG.4 TOP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET FIG.5 TOP WINNING STRATEGIES FIG.6 VALUE CHAIN ANALYSIS FIG.7 FINANCIAL REVENUES BY BUSINESS UNITS (2013) FIG.8 FINANCIAL REVENUES BY GEOGRAPHY(2013) FIG.9 SWOT ANALYSIS OF QIAGEN FIG.10 FINANCIAL REVENUE OF DAKO, BY SEGMENT (2012) FIG.11 SWOT ANALYSIS OF DAKO FIG.12 FINANCIAL REVENUE OF DAKO, BY SEGMENT FIG.13 FINANCIAL REVENUE OF DAKO, BY GEOGRAPHY FIG.14 SWOT ANALYSIS OF ROCHE FIG.15 REVENUE BY BUSINESS SEGMENTS FIG.16 REVENUE BY GEOGRAPHY FIG.17 SWOT ANALYSIS OF ABBOTT FIG.18 FINANCIAL REVENUES BY GEOGRAPHY FIG.19 FINANCIAL REVENUES BY TECHNOLOGY FIG.20 SWOT ANALYSIS OF BIOMERIEUX FIG.21 SWOT ANALYSIS OF VENTANA FIG.22 REVENUE BY DIAGNOSTIC TYPE FIG.23 SWOT ANALYSIS OF MYRAID FIG.24 SWOT ANALYSIS OF FERRISCAN FIG.25 SWOT ANALYSIS OF LEICA MICROSYSTEMS
FIG.26 REVENUE BY END MARKETS FIG.27 SWOT ANALYSIS OF LIFE TECHNOLOGIES
Contact Us: Sona Padman 5320 SW Macadam Avenue, Suite 100, Portland, OR 97239 United States Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 (U.S. & Canada) Fax: +1 (855) 550-5975 Email: sales@reportsandintelligence.com Web: http://www.reportsandintelligence.com/